WorksheetsISD3-P1
Total questions: 67
Worksheet time: 34mins
Name
Class
Date
1.
Nephelometry and immunoturbidimetry have been applied to the reading of agglutination reactions
a)
Particle-enhanced immunoassay
b)
Particle counting immunoassay (PACIA)
c)
Particle-enhanced turbidimetric inhibition immunoassay (PETINIA)
2.
▪ It involves measuring the number of residual non-agglutinating particles in a specimen
a)
Particle-enhanced immunoassay
b)
Particle counting immunoassay (PACIA)
c)
Particle-enhanced turbidimetric inhibition immunoassay (PETINIA)
3.
These particles are counted by means of a laser beam in an optical particle counter similar to the one that is designed to count blood cells
a)
Particle-enhanced immunoassay
b)
Particle counting immunoassay (PACIA)
c)
Particle-enhanced turbidimetric inhibition immunoassay (PETINIA)
4.
▪ As agglutination occurs, clumps of antigens increase in size, these large clumps are not counted. The amount of unknown antigen in a patient sample is therefore INDIRECTLY PROPORTIONAL to the number of unagglutinated particle
a)
Particle-enhanced immunoassay
b)
Particle counting immunoassay (PACIA)
c)
Particle-enhanced turbidimetric inhibition immunoassay (PETINIA)
5.
Specimen is incubated with latex beads coated with the analyte of interest and reagent antibody
a)
Particle-enhanced immunoassay
b)
Particle counting immunoassay (PACIA)
c)
Particle-enhanced turbidimetric inhibition immunoassay (PETINIA)
6.
If patient’s antigen is low, reagent antibody will bind to the latex beads, resulting to aggregate formation and high level of turbidity
a)
Particle-enhanced immunoassay
b)
Particle counting immunoassay (PACIA)
c)
Particle-enhanced turbidimetric inhibition immunoassay (PETINIA)
7.
COMPETITIVE ASSAY, INVERSELY PROPORTIONAL, USED ON THERAPETIC DRUGS
a)
Particle-enhanced immunoassay
b)
Particle counting immunoassay (PACIA)
c)
Particle-enhanced turbidimetric inhibition immunoassay (PETINIA)
8.
▪ If patient’s antigen is high, the antigen will bind to reagent antibody and prevent it from binding to latex beads, resulting in less turbidity
a)
Particle-enhanced immunoassay
b)
Particle counting immunoassay (PACIA)
c)
Particle-enhanced turbidimetric inhibition immunoassay (PETINIA)
9.
Antigen consists of very fine particles that clump together in a positive reaction
a)
Flocculation
b)
Neutralization
10.
Specific type of precipitation that occurs over a narrow range of antigen concentrations
a)
Flocculation
b)
Neutralization
11.
Examples: VDRL, RPR
a)
Flocculation
b)
Neutralization
12.
It measures the ability of the patient’s antibody to neutralize infectivity and protect cells from infection
a)
Flocculation
b)
Neutralization
13.
Antigenic activity is stopped by its specific antibody
a)
Flocculation
b)
Neutralization
14.
To detect toxins, viral agents, or antibodies to the toxin or viral agents
a)
Flocculation
b)
Neutralization
15.
Types ✓ Toxin neutralization (Schick test, Dick test, ASO titration test) ✓ Virus neutralization
a)
Flocculation
b)
Neutralization
16.
It is designed for antigens and antibodies that may be small in size or present in very low concentrations
a)
Labeled immunoassay
b)
Unlabeled immunoassay
17.
It is determined indirectly by using a labeled reactant to detect whether or not specific binding has taken place
a)
Labeled immunoassay
b)
Unlabeled immunoassay
18.
Most immunoassays use a solid phase vehicle for separation such polystyrene test tubes, microtiter plates, glass, or polystyrene beads, magnetic beads, plastic beads, and cellulose membrane
a)
Labeled immunoassay
b)
Unlabeled immunoassay
19.
No separation step is necessary
a)
Homogenous
b)
Heterogenous
20.
Enzyme-multiplied immunoassay technique (EMIT)
a)
Homogenous
b)
Heterogenous
21.
Cloned-enzyme donor immunoassay (CEDIA)
a)
Homogenous
b)
Heterogenous
22.
Fluorescence polarization immunoassay (FPIA)
a)
Homogenous
b)
Heterogenous
23.
Enzyme immunoassay (EIA)
a)
Homogenous
b)
Heterogenous
24.
Rapid immunoassays
a)
Homogenous
b)
Heterogenous
25.
Fluorescence immunoassay (FIA
a)
Homogenous
b)
Heterogenous
26.
Radioimmunoassay (RIA)
a)
Homogenous
b)
Heterogenous
27.
Electrochemiluminescence immunoassay (ECLIA)
a)
Homogenous
b)
Heterogenous
28.
Chemiluminescent microparticle immunoassay (CMIA)
a)
Homogenous
b)
Heterogenous
29.
Enzyme-linked immunosorbent assay (ELISA)
a)
Homogenous
b)
Heterogenous
30.
Emission of light caused by a chemical reaction, not from the light source
a)
Radioimmunoassay
b)
Enzyme immunoassay
c)
Fluorescent immunoassay
d)
Chemiluminiscent immunoassay
e)
Rapid Immunoassay
31.
▪ Chemiluminescence substances are luminol, acridinium esters, ruthenium derivatives, and nitrophenyl oxalates
a)
Radioimmunoassay
b)
Enzyme immunoassay
c)
Fluorescent immunoassay
d)
Chemiluminiscent immunoassay
e)
Rapid Immunoassay
32.
Measured in luminometer
Advantages: ✓ Excellent sensitivity ✓ Reagents are stable and relatively nontoxic ✓ Inexpensive to perform ✓ Faster TAT
a)
Radioimmunoassay
b)
Enzyme immunoassay
c)
Fluorescent immunoassay
d)
Chemiluminiscent immunoassay
e)
Rapid Immunoassay
33.
Membrane-based, easy to perform, and give reproducible results
a)
Radioimmunoassay
b)
Enzyme immunoassay
c)
Fluorescent immunoassay
d)
Chemiluminiscent immunoassay
e)
Rapid Immunoassay
34.
Designed primarily for point-of-care or home testing
a)
Radioimmunoassay
b)
Enzyme immunoassay
c)
Fluorescent immunoassay
d)
Chemiluminiscent immunoassay
e)
Rapid Immunoassay
35.
Lateral flow assay
a)
Radioimmunoassay
b)
Enzyme immunoassay
c)
Fluorescent immunoassay
d)
Chemiluminiscent immunoassay
e)
Rapid Immunoassay
36.
Uses fluorescent compounds known as fluorophores or fluorochromes as labels
a)
Radioimmunoassay
b)
Enzyme immunoassay
c)
Fluorescent immunoassay
d)
Chemiluminiscent immunoassay
e)
Rapid Immunoassay
37.
It uses enzyme labels immunoassays such as Horseradish peroxidase (HRP/APO), Glucose-6- phosphate dehydrogenase, Alkaline phosphatase, β-d-galactosidase
a)
Radioimmunoassay
b)
Enzyme immunoassay
c)
Fluorescent immunoassay
d)
Chemiluminiscent immunoassay
e)
Rapid Immunoassay
38.
Reacts with suitable substrates to produce breakdown products: Chromogenic, fluorogenic, or luminescent
a)
Radioimmunoassay
b)
Enzyme immunoassay
c)
Fluorescent immunoassay
d)
Chemiluminiscent immunoassay
e)
Rapid Immunoassay
39.
Pioneered by Yalow and Berson in the late 1950s
a)
Radioimmunoassay
b)
Enzyme immunoassay
c)
Fluorescent immunoassay
d)
Chemiluminiscent immunoassay
e)
Rapid Immunoassay
40.
It uses a radioactive substance label
a)
Radioimmunoassay
b)
Enzyme immunoassay
c)
Fluorescent immunoassay
d)
Chemiluminiscent immunoassay
e)
Rapid Immunoassay
41.
Gamma counter in Radioimmunoassay
a)
131 |
b)
125 |
c)
3 H
d)
14 C
42.
Beta counter in Radioimmunoassay
a)
131 |
b)
125 |
c)
3 H
d)
14 C
43.
Amount of bound labeled antibody is DIRECTLY PROPORTIONAL to the amount of patient analyte
a)
Competitive Radioimmunoassay (RIA)
b)
Non-competitive Radioimmunoassay (RIA) / IRMA
44.
Analyte being detected competes with a radiolabeled analyte for a limited number of binding sites
a)
Competitive Radioimmunoassay (RIA)
b)
Non-competitive Radioimmunoassay (RIA) / IRMA
45.
Amount of label in the bound phase is INVERSELY PROPORTIONAL to the amount of patient antigen present
a)
Competitive Radioimmunoassay (RIA)
b)
Non-competitive Radioimmunoassay (RIA) / IRMA
46.
Most sensitive for drug assay and hormone
a)
Competitive Radioimmunoassay (RIA)
b)
Non-competitive Radioimmunoassay (RIA) / IRMA
47.
based on the principles of RIA
a)
Competitive Enzyme-Linked Immunosorbent Assay
b)
Non-Competitive ELISA
c)
Capture Assay
48.
Enzyme activity is INVERSELY PROPORTIONAL to the concentration of the test substance
a)
Competitive Enzyme-Linked Immunosorbent Assay
b)
Non-Competitive ELISA
c)
Capture Assay
49.
Referred as indirect ELISA tests because the enzyme-labeled reagent does not participate in the initial antigen-antibody binding reaction
a)
Competitive Enzyme-Linked Immunosorbent Assay
b)
Non-Competitive ELISA
c)
Capture Assay
50.
Indirect ELISA
a)
Competitive Enzyme-Linked Immunosorbent Assay
b)
Non-Competitive ELISA
c)
Capture Assay
51.
Amount of enzyme label is DIRECTLY PROPORTIONAL to the amount of the test substance
a)
Competitive Enzyme-Linked Immunosorbent Assay
b)
Non-Competitive ELISA
c)
Capture Assay
52.
Solid phase support: microtiter plates, nitrocellulose membranes, magnetic, latex plastic beads
a)
Competitive Enzyme-Linked Immunosorbent Assay
b)
Non-Competitive ELISA
c)
Capture Assay
53.
Used to measure antibody production to infectious agents that are difficult to isolate in the laboratory and for autoantibody testing
a)
Competitive Enzyme-Linked Immunosorbent Assay
b)
Non-Competitive ELISA
c)
Capture Assay
54.
If antibody is bound to the solid phase, these assays are often called sandwich assays or immunometric assays. ▪ Enzymatic activity is directly proportional to the amount of antigen in the test sample
a)
Competitive Enzyme-Linked Immunosorbent Assay
b)
Non-Competitive ELISA
c)
Capture Assay
55.
Capture assays
a)
Directly proportional, non-competitive
b)
Indirectly proportional, competitive
56.
Absorbs maximally at 490 to 495 nm and emits a green color at 517 to 520 nm
a)
Fluorescein
b)
Tetrahylrhodamine
c)
hycoerythrin, europium (β-naphthyl trifluoroacetone), and Lucifer yellow VS
57.
Absorbs at 550 nm and emits red light at 580 to 585 nm
a)
Fluorescein
b)
Tetrahylrhodamine
c)
hycoerythrin, europium (β-naphthyl trifluoroacetone), and Lucifer yellow VS
58.
Antibody that is conjugated with a fluorescent tag is added directly to unknown antigen that is fixed to a microscope slide
a)
Direct Immunofluorescent Assay
b)
Indirect Immunofluorescent Assay
c)
Inhibition Immunofluorescent assay
d)
Fluorescence Polarization Immunoassay
59.
Slide is read using Fluorescence microscope
a)
Direct Immunofluorescent Assay
b)
Indirect Immunofluorescent Assay
c)
Inhibition Immunofluorescent assay
d)
Fluorescence Polarization Immunoassay
60.
Example of antigens detected by ____ include bacterial pathogens such as Legionella pneumophila and Chlamydia trachomatis
a)
Direct Immunofluorescent Assay
b)
Indirect Immunofluorescent Assay
c)
Inhibition Immunofluorescent assay
d)
Fluorescence Polarization Immunoassay
61.
2-step procedure
✓ Incubation of patient serum with a known antigen attached to a solid phase
✓ The slide is washed, and then an antihuman immunoglobulin containing a fluorescent tag is added
a)
Direct Immunofluorescent Assay
b)
Indirect Immunofluorescent Assay
c)
Inhibition Immunofluorescent assay
d)
Fluorescence Polarization Immunoassay
62.
▪ It is the principle employed in FANA testing and FTA-ABS test
a)
Direct Immunofluorescent Assay
b)
Indirect Immunofluorescent Assay
c)
Inhibition Immunofluorescent assay
d)
Fluorescence Polarization Immunoassay
63.
Can be used for either antigen or antibody identification
a)
Direct Immunofluorescent Assay
b)
Indirect Immunofluorescent Assay
c)
Inhibition Immunofluorescent assay
d)
Fluorescence Polarization Immunoassay
64.
It is a BLOCKING test in which antigen is first exposed to unlabeled antibody, then to labeled antibody, then to labeled antibody, and is finally washed and examined.
If the unlabeled and labeled antibodies are both homologous to the antigen, there should be no fluorescence
a)
Direct Immunofluorescent Assay
b)
Indirect Immunofluorescent Assay
c)
Inhibition Immunofluorescent assay
d)
Fluorescence Polarization Immunoassay
65.
It is based on the change in polarization of fluorescent light emitted from a labeled molecule when it is bound by antibody
a)
Direct Immunofluorescent Assay
b)
Indirect Immunofluorescent Assay
c)
Inhibition Immunofluorescent assay
d)
Fluorescence Polarization Immunoassay
66.
Labeled antigens compete with unlabeled antigen in the patient sample for a limited number of antibody binding sites
a)
Direct Immunofluorescent Assay
b)
Indirect Immunofluorescent Assay
c)
Inhibition Immunofluorescent assay
d)
Fluorescence Polarization Immunoassay
67.
Degree of fluorescence polarization is INVERSELY PROPORTIONAL to concentration of the analyte
a)
Direct Immunofluorescent Assay
b)
Indirect Immunofluorescent Assay
c)
Inhibition Immunofluorescent assay
d)
Fluorescence Polarization Immunoassay
100 %
